ExploreWatchlistsPricing
  1. JP-listed companies
  2. DAIICHI SANKYO COMPANY, LIMITED
  3. Financials
  4. Stockholders' equity

DAIICHI SANKYO COMPANY, LIMITED (4568)

Market cap
¥5.29T
P/E ratio
17.8x
Daiichi Sankyo is a global pharmaceutical company that researches, develops and sells prescription drugs and over-the-counter medicines worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20251,623,416-3.86%
Mar 31, 20241,688,603+16.79%
Mar 31, 20231,445,854+7.03%
Mar 31, 20221,350,872+6.20%
Mar 31, 20211,272,053-2.62%
Mar 31, 20201,306,274+4.53%
Mar 31, 20191,249,705+43.21%
Mar 31, 2018872,659-1.78%
Mar 31, 2017888,519-9.83%
Mar 31, 2016985,391-8.26%
Mar 31, 20151,074,160+30.38%
Mar 31, 2014823,864

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat